Robert E. Bellet

1.7k total citations
35 papers, 1.4k citations indexed

About

Robert E. Bellet is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Robert E. Bellet has authored 35 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Oncology, 9 papers in Molecular Biology and 8 papers in Immunology. Recurrent topics in Robert E. Bellet's work include Cancer Treatment and Pharmacology (10 papers), Immunotherapy and Immune Responses (7 papers) and Cutaneous Melanoma Detection and Management (6 papers). Robert E. Bellet is often cited by papers focused on Cancer Treatment and Pharmacology (10 papers), Immunotherapy and Immune Responses (7 papers) and Cutaneous Melanoma Detection and Management (6 papers). Robert E. Bellet collaborates with scholars based in United States, United Kingdom and France. Robert E. Bellet's co-authors include Michael J. Mastrangelo, David Berd, Vicente Valero, Giuseppe Fraschini, R S Walters, Frankie A. Holmes, Leticia Esparza, Gustavo Fonseca, Gabriel N. Hortobágyi and Aman U. Buzdar and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

Robert E. Bellet

35 papers receiving 1.3k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Robert E. Bellet 1.0k 349 345 217 180 35 1.4k
Lydia Sánchez 580 0.6× 224 0.6× 642 1.9× 213 1.0× 132 0.7× 25 1.3k
Andrea Warrick 607 0.6× 316 0.9× 499 1.4× 185 0.9× 139 0.8× 25 1.2k
Howard Fingert 1.1k 1.0× 209 0.6× 765 2.2× 100 0.5× 63 0.3× 47 1.9k
Catalin Mihalcioiu 422 0.4× 283 0.8× 391 1.1× 155 0.7× 131 0.7× 38 1000
Holger W. Hirte 978 0.9× 305 0.9× 763 2.2× 271 1.2× 60 0.3× 46 2.0k
Dagmar Hess 897 0.9× 267 0.8× 880 2.6× 243 1.1× 58 0.3× 61 1.7k
Alessandra Bersiga 641 0.6× 658 1.9× 458 1.3× 149 0.7× 32 0.2× 31 1.2k
M Giai 460 0.4× 268 0.8× 474 1.4× 165 0.8× 38 0.2× 33 1.2k
J.H. Holzner 364 0.3× 178 0.5× 292 0.8× 100 0.5× 35 0.2× 49 858
Massimo Fanelli 423 0.4× 310 0.9× 555 1.6× 64 0.3× 49 0.3× 26 1.0k

Countries citing papers authored by Robert E. Bellet

Since Specialization
Citations

This map shows the geographic impact of Robert E. Bellet's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert E. Bellet with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert E. Bellet more than expected).

Fields of papers citing papers by Robert E. Bellet

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert E. Bellet. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert E. Bellet. The network helps show where Robert E. Bellet may publish in the future.

Co-authorship network of co-authors of Robert E. Bellet

This figure shows the co-authorship network connecting the top 25 collaborators of Robert E. Bellet. A scholar is included among the top collaborators of Robert E. Bellet based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert E. Bellet. Robert E. Bellet is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Fracasso, Paula M., Joel Picus, Sherry A. Goodner, et al.. (2008). Phase 1 and pharmacokinetic study of weekly docosahexaenoic acid-paclitaxel, Taxoprexin®, in resistant solid tumor malignancies. Cancer Chemotherapy and Pharmacology. 63(3). 451–458. 40 indexed citations
3.
Bellet, Robert E., Hassan Ghazal, Marshall S. Flam, et al.. (2007). A phase III randomized controlled study comparing iron sucrose intravenously (IV) to no iron treatment of anemia in cancer patients undergoing chemotherapy and erythropoietin stimulating agent (ESA) therapy. Journal of Clinical Oncology. 25(18_suppl). 9109–9109. 16 indexed citations
4.
Bellet, Robert E., Daniel P. Petrylak, Basil Kasimis, et al.. (2004). Phase II study of DHA-paclitaxel (TXP) as first line chemotherapy in patients with hormone refractory prostate cancer (HRPC). Journal of Clinical Oncology. 22(14_suppl). 4657–4657. 3 indexed citations
5.
Petit, Thierry, Howard A. Burris, Peter M. Ravdin, et al.. (1999). A phase I study of docetaxel and 5-fluorouraciI in patients with advanced solid malignancies. Annals of Oncology. 10(2). 223–230. 13 indexed citations
6.
Ravdin, P., Howard A. Burris, Gary Cook, et al.. (1995). Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.. Journal of Clinical Oncology. 13(12). 2879–2885. 275 indexed citations
7.
Valero, Vicente, Frankie A. Holmes, R S Walters, et al.. (1995). Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer.. Journal of Clinical Oncology. 13(12). 2886–2894. 325 indexed citations
8.
Mastrangelo, Michael J., et al.. (1989). The importance of tamoxifen to a cisplatin-containing regimen in the treatment of metastatic melanoma. Cancer. 63(7). 1292–1295. 93 indexed citations
9.
McClay, Edward F., Michael J. Mastrangelo, Robert E. Bellet, & David Berd. (1987). Combination chemotherapy and hormonal therapy in the treatment of malignant melanoma.. PubMed. 71(5). 465–9. 81 indexed citations
10.
McClay, Edward F. & Robert E. Bellet. (1987). Preoperative Evaluation of the Oncology Patient. Medical Clinics of North America. 71(3). 529–540. 1 indexed citations
11.
Bellet, Robert E., et al.. (1980). Primary Choroidal and Cutaneous Melanomas Occurring in a Patient with the B-K Mole Syndrome Phenotype. American Journal of Ophthalmology. 89(4). 567–570. 41 indexed citations
12.
Bellet, Robert E., et al.. (1979). Evaluation of a “Nude” Mouse-Human Tumor Panel as a Predictive Secondary Screen for Cancer Chemotherapeutic Agents<xref ref-type="fn" rid="FN2">2</xref>. JNCI Journal of the National Cancer Institute. 63(5). 1185–8. 43 indexed citations
13.
Bellet, Robert E., Robert B. Catalano, Michael J. Mastrangelo, & David Berd. (1978). Phase II study of subcutaneously administered 5‐azacytidine (NSC‐102816) in patients with metastatic malignant melanoma. Medical and Pediatric Oncology. 4(1). 11–15. 7 indexed citations
14.
Bellet, Robert E., et al.. (1977). A phase II evaluation of bacillus calmette‐guerin plus megestrol acetate in patients with metastatic renal adenocarcinoma. Medical and Pediatric Oncology. 3(3). 237–242. 6 indexed citations
15.
Bellet, Robert E., et al.. (1977). Multiple primary malignancies in patients with cutaneous melanoma. Cancer. 40(S4). 1974–1981. 47 indexed citations
16.
Bodurtha, A., et al.. (1977). A phase II study of autologous irradiated tumor cells plus BCG in patients with metastatic malignant melanoma. Cancer. 40(5). 2091–2093. 32 indexed citations
17.
Bellet, Robert E., et al.. (1976). A Study of Antitumor (Phase II) and Immunosuppressive Effects of ICRF‐159 in Patients with Metastatic Melanoma. The Journal of Clinical Pharmacology. 16(8-9). 433–438. 2 indexed citations
18.
Bellet, Robert E., et al.. (1974). Estrogen-induced Hypernephroma. The Journal of Urology. 112(2). 160–161. 12 indexed citations
19.
Bellet, Robert E., Michael J. Mastrangelo, P F Engstrom, & R P Custer. (1973). Hepatotoxicity of 5-azacytidine (NSC-102816) (a clinical and pathologic study).. PubMed. 20(3). 303–9. 13 indexed citations
20.
Weiss, Arthur J., et al.. (1972). Phase I study of 5-azacytidine (NSC-102816) .. PubMed. 56(3). 413–9. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lydia Sánchez Breakdown of academic impact, for papers by Andrea Warrick Breakdown of academic impact, for papers by Howard Fingert Breakdown of academic impact, for papers by Catalin Mihalcioiu Breakdown of academic impact, for papers by Holger W. Hirte Breakdown of academic impact, for papers by Dagmar Hess Breakdown of academic impact, for papers by Alessandra Bersiga Breakdown of academic impact, for papers by M Giai Breakdown of academic impact, for papers by J.H. Holzner Breakdown of academic impact, for papers by Massimo Fanelli
Rankless by CCL
2026